Regeneron Pharmaceuticals' Net Cash Flow rose 501.33% to $497.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $501.4 million, marking a year-over-year increase of 437.42%. This contributed to the annual value of -$248.1 million for FY2024, which is 34.92% up from last year.
According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' Net Cash Flow is $497.9 million, which was up 146.20% from -$1.1 billion recorded in Q2 2025.
In the past 5 years, Regeneron Pharmaceuticals' Net Cash Flow registered a high of $1.4 billion during Q3 2021, and its lowest value of -$2.0 billion during Q2 2023.
Over the past 3 years, Regeneron Pharmaceuticals' median Net Cash Flow value was $210.7 million (recorded in 2023), while the average stood at -$55.1 million.
Per our database at Business Quant, Regeneron Pharmaceuticals' Net Cash Flow crashed by 4,105.47% in 2023 and then soared by 573.25% in 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Net Cash Flow (Quarterly) stood at -$546.8 million in 2021, then rose by 29.52% to -$385.4 million in 2022, then spiked by 249.82% to $577.4 million in 2023, then declined by 17.23% to $477.9 million in 2024, then spiked by 501.33% to $497.9 million in 2025.
Its Net Cash Flow was $497.9 million in Q3 2025, compared to -$1.1 billion in Q2 2025 and $603.4 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value